Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by juniper88on Mar 23, 2022 8:29pm
135 Views
Post# 34539845

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Stay focused on the facts

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Stay focused on the factsI don't believe that patient #2 was stopped at cycle 4. The chart simply doesn't put the dashed boxes beyond the 300mg/m2 level.
jfm1330 wrote: You are right that 300 mg/m2 could be a good dose, but it would be the case only with a proof of concept. Also, yes having the highest possible dosage is not a necissity, if you have the proof of concept. As I said in my previous message, at this point if the 420 mg/m2 was the MTD, it would be in itself a very strong indication that we have a proof of concept because I think it would be impossible to tlerate that dose if the concept was not working. At 300 mg/m2, we cannot be sure, and 300 mg/m2 is not even confirmed as a tolerable dose. All the idea that lower doses are valid only works if the concept works. That leads us to patient #2. OK, he gor 4 cycles, but three of these four cycles were at doses below the MTD of docetaxel alone. So it tells us nothing about the proof of concept, and why was it stopped after one cycle at 300 mg/m2? In my opinion, we cannot read anything into that. At this point this trias is a black box with known input, an very little know on the output. Also, Marsolais can say all he wants that the concept of having the highest possible dose is nor correct, but he is right and wrong on that. If you have the proof of concept he is right to a certain extent, but at this point a 300 mg/m2 dose sows doubt about the existence of a proof of concept. Also, even with a proof, you ideally want the MTD to be as high as possible because it would give you a wider therapeutic window, and would allow long term treatment at lower doses. If 300 mg/m2 is tolerable, but very close to the MTD, or the MTD, it means that you would need to go quite low on dosage for longer term use. Also, to be able to use higher doses would have been a desirable therapeutic option nonetheless.

juniper88 wrote: Yes, "we" [the people reading this board] do not have much of a hint of proof of concent.  Perhaps, patient #2 being on the treatment for 4 cycles could be considered a "hint".  Either way, the investiigators might have hints that we simple do not know about.  And these hints might have startted at lower doses than 300mg/m2.  If I am right about patient #2 then a hint might have started at 60mg/m2.  The concept of having to go to the highest possible dosage simply is not correct.  And as Christian once told me, I understand the science just fine.




<< Previous
Bullboard Posts
Next >>